Characteristics and prevalence of non-classical congenital adrenal hyperplasia with a V281l mutation in patients with premature pubarche

Erdeve S. S., BERBEROĞLU M., KUTLAY N., ŞIKLAR Z., Hacihamdioglu B., Tukun A., ...More

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, vol.24, no.11-12, pp.965-970, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 11-12
  • Publication Date: 2011
  • Doi Number: 10.1515/jpem.2011.354
  • Journal Name: JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.965-970
  • Keywords: children, 21-hydroxylase deficiency, non-classical congenital adrenal hyperplasia, premature pubarche, V281L mutation, STEROID 21-HYDROXYLASE DEFICIENCY, ISOLATED PRECOCIOUS PUBARCHE, HYPERANDROGENIC WOMEN, SPLICING MUTATION, MOLECULAR DEFECTS, PUBERTAL CHANGES, CYP21 GENE, GIRLS, IDENTIFICATION, HETEROGENEITY
  • Ankara University Affiliated: Yes

Abstract

We aimed to determine the prevalence and clinical characteristics of non-classical congenital adrenal hyperplasia (NCCAH) with V281L mutation in patients with premature pubarche. An adrenocorticotrophic hormone (ACTH) stimulation test was performed in 14 of the 159 patients with premature pubarche (PP). Patients whose stimulated 17 alpha-hydroxyprogesterone (17-OHP) level on the ACTH test was >= 10 ng/mL underwent a mutational analysis of the CYP21 gene. NCCAH was defined in nine (5.7%) patients, all of whom had the V281L mutation. Four of the NCCAH patients were homozygote and four of them were heterozygote. One other patient was compound heterozygote for V281L mutation and the I2 splice mutation. One of the patients with V281L heterozygous mutation developed true precocious puberty and the other one had rapid progressive early puberty and developed polycystic ovary syndrome. ACTH stimulated 17-OHP >= 10 ng/mL in PP patients is load star to mutation analysis and heterozygote patients should be followed for clinical and biological hyperandrogenism up to completion of the whole 'genome sequence'.